Free Cash Flow

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

The water solutions giant unveiled ambitious new financial targets, aiming to capitalize on water scarcity and infrastructure needs while reassuring investors.

The miner renewed its bid to buy back 5% of its stock, but its history of low execution raises questions about its commitment to the major capital plan.

Predactiv launches a 'push button' lookalike modeling feature, enabling businesses to turn proprietary data into new revenue streams without heavy engineering.

At its 90th anniversary, the Ford Foundation appoints Jason W. Ingle, Henry Ford's great-great-grandson, signaling a new chapter blending legacy with impact investing.

Unifi launches Luxel, a new yarn blending linen's feel with performance tech and circular recycling, aiming to redefine sustainable fashion and home goods.

Techtronic Industries reports record profits driven by its MILWAUKEE and RYOBI brands, even as it navigates tariffs and restructures its struggling floorcare unit.

Once a failing firm, Aurelion Inc. bet its future on tokenized gold. The gamble paid off with a profitable quarter, but regulatory risks loom large.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

The digital asset giant is delisting from Toronto to streamline costs, a move that reshapes its buyback plan and how Canadian investors trade its stock.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

A major renewal with a 30M-client bank highlights the industry's shift to biometrics, boosting BIO-key's finances and solidifying its market niche.

Post-listing, the Swiss HealthTech firm pushes for US market expansion and European reimbursement, streamlining its focus on AI-powered brain health.

Hong Kong's Ming Shing Group replaces its CFO and CAO, bringing in a new financial architect as its stock tumbles and it navigates a risky Bitcoin bet.

EcoVadis awards highlight a major shift: sustainability is no longer about compliance, but a core driver of performance, resilience, and long-term value.

The biopharma company's strategic bid for non-dilutive funding could advance a first-in-class therapy for severe, untreated skin conditions.

Ag Growth International brings back its 23-year former CFO to the board, signaling a major push for operational excellence amid financial pressures.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.